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SSRI treatment. METHODS: Electronic medical records
and medication profiles from HMO patients were retro-
spectively reviewed. Inclusion criteria were patients over
18 years old with a new prescription for an SSRI who
were continuously enrolled in the HMO plan for at least
one year (6 months before and 6 months after their index
date). The perspective was that of the HMO. RESULTS:
Of the 464 patients who met the inclusion criteria, 130
patients (28%) had 144 medication changes made after
initial therapy, including 43 additions of medication, 43
switches to another antidepressant, 41 discontinuations
of therapy due to side effects, and 17 dose changes due to
side effects. A total of 160 patients (34%) had at least
one side effect of the SSRI noted in their medical record.
Costs to treat side effects were estimated for changes/
additions of medication that appeared in the medication
profiles (38 patients). The cost of added medications that
were noted in the medical record but did not appear in
the medication profile (e.g. non-prescription items such
as Immodium) were not included in the estimate due to
the perspective of the study. Other costs associated with
side effects included physician visits (43 patients), lab
tests for dosage adjustments (4 patients), and emergency
room visits (3 patients). Sensitivity analyses indicated that
the direct medical costs associated with the treatment of
side effects ranged from approximately $4600 US to $6000
US for the 464 patients ($10 US-$13 US per patient) for
the six-month period of analysis. CONCLUSION: Al-
though one-third of patients noted at least one side effect
of SSRI treatment, the direct medical costs associated
with the side effects were relatively small. Future studies
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OBJECTIVE: Pamidronate prevents skeletal-related events
in breast cancer patients with skeletal metastasis, but it
costs $175 per month and published cost-utility analyses
have yielded conflicting results. The purpose of our study
was to rigorously evaluate the cost-utility of pamidr-
onate. METHODS: We considered two hypothetical co-
horts of woman with metastatic breast cancer receiving
or not pamidronate (90 mg every 28 days). We developed
a 24-month-long Markov chain including 5 health states
related to skeletal metastases (chronic bone pain, acute
fracture, vertebral or non-vertebral, post-fracture, verte-
bral or non-vertebral) and death. Probabilities of clinical
outcomes were obtained from two randomized clinical
trials addressing chemotherapy-treated (CTPs) and hor-
mone-treated (HTPs) patients. Cost estimates were de-
rived from local hospital charges and market cost of
drugs. Quality of life estimates were obtained with a
structured time trade-off interview of 20 health care
workers. Cost-effectiveness was calculated from the per-
spective of the National Health Care System. RESULTS:
At baseline analysis, life expectancy of pamidronate was
13 quality-adjusted days in CTPs and 30 days in HTPs,
while incremental cost was $1469 in CTPs and $2275 in
HTPs. The incremental cost per QALY gained was $40
in CTPs and $27,857 in HTPs. Sensitivity analysis re-
vealed that the results depended on: 1) the quality of life
correlated with the primary disease, threshold values be-
ing 0.30 (baseline 0.33) in CTPs and 0.42 (baseline 0.73)
in HTPs; 2) the quality of life on pamidronate, threshold
being 0.27 (baseline 0.28) in CTPS and 0.58 in HTPs
(baseline 0.62). and 0.83. CONCLUSIONS: Based upon
the results of this analysis we can conclude that pamidro-
nate is cost-effective in reducing skeletal events of pa-
tients with metastatic breast cancer undergoing chemo-
or hormone-therapy. The variation of the estimates among
the present and the two previous studies can be explained
in terms of model and country differences.
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OBJECTIVE: The objective of this study was to assess
the relationship between haemoglobin levels and quality
of life in cancer patients, looking specifically at breast,
ovarian, lung, and multiple myeloma patients. METH-
ODS: This was a multi-centre cross-sectional study. A to-
tal of 198 patients were recruited from six sites across the
United Kingdom. Patients were asked to complete the
FACT-An, SF-36, and Patient Generated Index (PGI)
upon having their Hb level assessed during a routine
clinic visit. RESULTS: 38% of the patients recruited into
the study had breast cancer, 27% ovarian, 25% lung,
and 10% multiple myeloma. The mean Hb level was
10.9. Analyses were conducted on the data controlling
for age, gender, and time since diagnosis. Significant rela-
tionships were found between all domains of the FACT
with the exception of the social/family domain. Signifi-
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cant relationships were found between all domains on the
SF-36 with the exception of emotional role limitation and
pain. A regression analysis showed that Hb accounts for
7% of the variability of the fatigue scale of the FACT and
that on this scale a 1 unit rise in Hb equals a rise of 6.27
units. In addition, Hb accounts for an additional 7% of
variability of FACT-An scores and 1 unit rise in Hb
equals a rise of 7.31 units. On average, Hb accounts for
an additional 7% of the variability of the SF-36 scales,
and a 1 unit rise in Hb equals a rise of 7.00 units in SF-36
scales. The PGI showed no relationship with Hb levels.
CONCLUSION: Quality of life as measured by the FACT-
An and the SF-36 is significantly related to Hb levels in
U.K. cancer patients. This indicated that optimization of
patient Hb is likely to increase the quality of life in cancer
patients.
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OBJECTIVE: to estimate the costs and effects of pami-
dronate vs placebo in prevention of bone complications
in metastastic breast cancer in Poland. METHODS: The
model for the Polish health-care context was developed,
based on the use of clinical data from literature and local
data on health-care resource utilization and unit cost.
Only direct medical costs were analyzed. The perspective
of health-care payers and time horizon of 18 months
were taken. In the cost-effectiveness analysis the primary
clinical outcomes for measuring success in the analysis
were the avoided skeletal related events (SRE), which
were defined as pathological fractures, irradiation and
episodes of hypercalcaemia. In the cost-utility analysis
QALY values measured in the analysis were patients
preferences for alternative health outcomes, reported in
the randomized trial. The cost-effectiveness threshold,
calculated on the basis of cost of 1-year haemodialysis
treatment (62 400 PLN, 1 USD  4,5 PLN), was sug-
gested to assess if pamidronate therapy should be adopted.
The one-way sensitivity analysis and threshold analysis
were performed. RESULTS: The costs of avoiding of SRE
for pamidronate vs placebo was 3420 PLN (taking into
consideration lowest costs of treatment of pathological
fractures) or, taking into consideration highest costs of
treatment of pathological fractures, pamidronate treat-
ment was dominant program (129 SRE avoided and 42
546 PLN/100patients/year saved). The cost/QALY gained
was 45 021 PLN or pamidronate was the dominant pro-
gram (9,8 QALY gained and 42 546 PLN/100 patients/
year saved). The results were most sensitive to the costs
of treatment of pathological fractures and number of
SRE avoided. CONCLUSION: Comparing this outcome
with suggested threshold for cost-effectiveness it was
concluded that prophylactic pamidronate therapy for ad-
vanced breast cancer offers substantial benefit at reason-
able cost to the Polish health care system. By assumption
that all pathological fractures would be treated with most
costly methods, pamidronate might be dominant program. 
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Capecitabine is an oral fluoropyrimidine which mimics
continuous 5-FU and is preferentially activated by thymi-
dine phosphorylase to 5-FU within tumor cells. A ran-
domized phase III clinical trial, comparing capecitabine
(n  301, 1250 mg/m2/bid 
 14d, q3 weeks) vs. M-regi-
men (n  301, 5-FU 425 mg/m2; LCV 20 mg/m2 d1-5,
q4 weeks) resulted in a superior response rate (26.6% vs.
17.9%, P  0.013), equivalent progression-free survival
(5.3 vs 4.8 months, HR (hazard ratio) 0.96), equivalent
overall survival (13.2 vs 12.4 months, HR 0.91), and a
superior safety profile for capecitabine. The most remark-
able differences in AEs requiring treatment were lower
rates of infections/sepsis, stomatitis, vomiting, and diar-
rhea and a higher rate of hand-foot syndrome (HFS) for
capecitabine-treated patients. OBJECTIVE: To evaluate
the economic consequences of differences in the AE-pro-
file of capecitabine and M-regimen in colorectal cancer.
METHODS: Patients were recruited from 66 centers in 8
EU-countries, Australia, New Zealand, Russia, Israel and
Taiwan. Data on hospital use, AEs requiring medications
or procedures, and all physician encounters were col-
lected during the clinical trial for all randomized patients
and analyzed. RESULTS: Total days in hospital for: sto-
matitis/mucosal inflammation, HFS, neutropenia, pyr-
exia, infections, diarrhea, nausea and vomiting was re-
duced by 172 hospital days (339 vs. 167, 51%) in the
capecitabine arm. The use of antifungals was reduced by
34% and the usage of 5-HT3-antagonists by 39% in the
capecitabine arm. Although not used frequently, con-
sumption of octreotide and G-CSF was reduced substantially
(100% and 59% respectively) in the capecitabine-treated
group. Overall use of high-cost medication including
cephalosporins and fluoroquinolones was reduced by
56%. Procedures and unscheduled outpatient-visits were
